Cancers & treatments·Regimen libraryFirst line

Nivolumab + ipilimumab + 2 cycles of platinum doublet

Checked 2026-09-09

Metastatic NSCLC without EGFR/ALK alteration, first line

One cycle

every 21 days

21-day cycle, chemotherapy 2; nivolumab up to 2 yearsIntravenous

Components

Drug	Dose	Route	Days	Note
Nivolumab Monoclonal antibody (anti-PD-1)	360 mg	IV	D1
Ipilimumab Monoclonal antibody (anti-CTLA-4)	1 mg/kg every 6 weeks	IV	D1	alternate cycles
Platinum doublet by histology Cytotoxic chemotherapy (platinum)	cycles 1-2 only	IV	D1

Cycles

chemotherapy 2; nivolumab up to 2 years

21-day cycle

Emetogenicity

Moderate (30-90%)

G-CSF

Not routine

Used in

Non-small-cell lung cancer

Products

NivolumabIpilimumabCarboplatin

Source

CheckMate 9LA, Lancet Oncology 2021

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.